Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S.

Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678.

2.

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Mar 7. pii: haematol.2018.209080. doi: 10.3324/haematol.2018.209080. [Epub ahead of print]

3.

Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response.

Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM.

Cytometry A. 2019 Apr;95(4):442-449. doi: 10.1002/cyto.a.23737. Epub 2019 Mar 5.

PMID:
30838773
4.

NK cells specifically TCR-dressed to kill cancer cells.

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S.

EBioMedicine. 2019 Feb;40:106-117. doi: 10.1016/j.ebiom.2019.01.031. Epub 2019 Jan 18.

5.

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.

6.

Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP.

J Hematol Oncol. 2018 Feb 20;11(1):23. doi: 10.1186/s13045-018-0561-0.

7.

Human c-SRC kinase (CSK) overexpression makes T cells dummy.

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S.

Cancer Immunol Immunother. 2018 Apr;67(4):525-536. doi: 10.1007/s00262-017-2105-9. Epub 2017 Dec 16.

PMID:
29248956
8.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

9.

BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5.

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH.

PLoS One. 2017 May 10;12(5):e0177188. doi: 10.1371/journal.pone.0177188. eCollection 2017.

10.

Defective IL-4 signaling in T cells defines severe common variable immunodeficiency.

Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J.

J Autoimmun. 2017 Jul;81:110-119. doi: 10.1016/j.jaut.2017.04.004. Epub 2017 May 3.

PMID:
28476239
11.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.

12.

Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.

Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K.

Cytometry B Clin Cytom. 2017 Jan;92(1):79-87. doi: 10.1002/cyto.b.21498.

13.

Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency.

Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B.

Clin Immunol. 2017 Feb;175:69-74. doi: 10.1016/j.clim.2016.11.014. Epub 2016 Dec 3.

PMID:
27919819
14.

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.

PMID:
27341313
15.

Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK.

Immunology. 2016 Sep;149(1):62-73. doi: 10.1111/imm.12629. Epub 2016 Jul 25.

16.

New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX.

Dale Rein I, Stokke C, Jalal M, Myklebust JH, Patzke S, Stokke T.

Cell Cycle. 2015;14(20):3261-9. doi: 10.1080/15384101.2015.1087617.

17.

Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.

Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A.

Biol Blood Marrow Transplant. 2015 May;21(5):840-7. doi: 10.1016/j.bbmt.2014.12.027. Epub 2015 Feb 14.

18.

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.

Exp Hematol. 2015 May;43(5):352-363.e4. doi: 10.1016/j.exphem.2015.01.008. Epub 2015 Jan 29.

19.

Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB.

Blood. 2014 Feb 13;123(7):1051-4. doi: 10.1182/blood-2013-07-512392. Epub 2013 Dec 19.

20.

Signaling pathways in lymphoma: pathogenesis and therapeutic targets.

Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody JD.

Future Oncol. 2013 Oct;9(10):1549-71. doi: 10.2217/fon.13.113. Review.

PMID:
24106904
21.

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R.

Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7.

22.

Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.

Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA.

Blood. 2013 Feb 28;121(9):1604-11. doi: 10.1182/blood-2012-09-457283. Epub 2013 Jan 7.

23.

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A.

BMC Cancer. 2012 Oct 16;12:478. doi: 10.1186/1471-2407-12-478.

24.

Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma.

Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH.

PLoS One. 2012;7(10):e46117. doi: 10.1371/journal.pone.0046117. Epub 2012 Oct 1.

25.

Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients.

Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A.

Br J Haematol. 2012 Dec;159(5):604-8. doi: 10.1111/bjh.12073. Epub 2012 Oct 9. No abstract available.

26.

SARA is dispensable for functional TGF-β signaling.

Bakkebø M, Huse K, Hilden VI, Forfang L, Myklebust JH, Smeland EB, Oksvold MP.

FEBS Lett. 2012 Sep 21;586(19):3367-72. doi: 10.1016/j.febslet.2012.07.027. Epub 2012 Jul 20.

27.

Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7.

Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, Stokke T, Smeland EB, Myklebust JH.

Eur J Immunol. 2011 Nov;41(11):3135-45. doi: 10.1002/eji.201141558. Epub 2011 Oct 18.

28.

The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells.

Tkacz-Stachowska K, Lund-Andersen C, Velissarou A, Myklebust JH, Stokke T, Syljuåsen RG.

Radiother Oncol. 2011 Oct;101(1):24-7. doi: 10.1016/j.radonc.2011.05.060. Epub 2011 Jun 30.

PMID:
21722983
29.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R.

Blood. 2011 Aug 4;118(5):1350-8. doi: 10.1182/blood-2011-03-345272. Epub 2011 Jun 13.

30.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R.

Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044.

31.

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.

Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12747-54. doi: 10.1073/pnas.1002057107. Epub 2010 Jun 11.

32.

CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas.

Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, Levy R, Levy S, Natkunam Y.

Hum Pathol. 2010 Feb;41(2):271-80. doi: 10.1016/j.humpath.2009.07.022. Epub 2009 Dec 8.

33.

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R.

Blood. 2009 Oct 15;114(16):3431-8. doi: 10.1182/blood-2009-05-223958. Epub 2009 Jul 29.

34.

A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients.

Gentles AJ, Alizadeh AA, Lee SI, Myklebust JH, Shachaf CM, Shahbaba B, Levy R, Koller D, Plevritis SK.

Blood. 2009 Oct 8;114(15):3158-66. doi: 10.1182/blood-2009-02-202465. Epub 2009 Jul 27.

35.

Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells.

Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH.

Eur J Immunol. 2007 Oct;37(10):2937-48.

36.

Characterization of early stages of human B cell development by gene expression profiling.

Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB.

J Immunol. 2007 Sep 15;179(6):3662-71. Erratum in: J Immunol. 2009 May1;182(9):5882.

37.

Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer.

Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N.

Int J Cancer. 2007 Oct 1;121(7):1433-44.

38.

PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells.

Sivertsen EA, Hystad ME, Gutzkow KB, Døsen G, Smeland EB, Blomhoff HK, Myklebust JH.

Br J Haematol. 2006 Oct;135(1):117-28.

PMID:
16965383
39.

BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3.

Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E.

Exp Hematol. 2006 Jan;34(1):72-81.

PMID:
16413393
40.
41.

BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1.

Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH.

BMC Immunol. 2005 May 9;6:9.

42.

Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells.

Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB.

Exp Hematol. 2002 Sep;30(9):990-1000.

PMID:
12225790
43.
44.
45.

Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma.

Fosså A, Brandhorst D, Myklebust JH, Seeber S, Nowrousian MR.

Exp Hematol. 1999 Nov;27(11):1621-6.

PMID:
10560909
46.

Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis.

Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB.

Exp Hematol. 1999 Sep;27(9):1451-9.

PMID:
10480436
47.

Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression.

Myklebust JH, Josefsen D, Blomhoff HK, Levy FO, Naderi S, Reed JC, Smeland EB.

J Cell Physiol. 1999 Jul;180(1):71-80.

PMID:
10362019
48.

Generation and characterization of gp100 peptide-specific NK-T cell clones.

Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G.

Int J Cancer. 1998 Mar 2;75(5):794-803.

Supplemental Content

Loading ...
Support Center